A phase 3 clinical trial with ISIS-TTRRx, a 2nd-generation antisense oligonucleotide targeting transthyretin (TTR), for the treatment of TTR amyloid cardiomyopathy. Issue 1 (December 2015) - Millns, Helen; Bergemann, Rito; Ackermann, Elizabeth; Monia, Brett; Lukas, Mary